

T: +1 607 565 3175

Physical Address: 1479 Talmadge Hill South, Waverly, NY 14892, USA

www.clinvet.com

## 14 May 2020 – Clinvet & Marshall Joint Letter to Customers

## Clinvet expands joint venture with Marshall BioResources in the US.

Clinvet and Marshall BioResources are proud to announce an expansion to our existing joint venture to increase capacity at our clinical research site, Clinvet USA, LLC., in Waverly, New York. The agreement will allow Clinvet to significantly increase capacity by incorporating research buildings at the current Marshall animal production facility based in Waverly and add additional highly experienced resources to Clinvet's research team. This agreement will ensure that Clinvet may offer additional capacity, more resources and faster start-up times for our US based customers.

Clinvet is diligently working to integrate the newly acquired facilities under the guidance of Dr Josephus Fourie. This includes, but is not limited to, implementing the necessary systems, infrastructure, and procedures to ensure the site conforms to local, international, and Clinvet's standards for animal welfare and quality in research.

Clinvet will add approximately 2,800 square meters (~30,000 square feet) to its current capacity. This will include a state-of-the-art necropsy and surgical suite for major operating procedures, feed/bedding warehouses, several barrier facilities with shower entry and exit to allow for isolated housing, specific to study requirements and other animal housing facilities. The facilities also allow for individually housed animals or group housing for both felines and canines. Depending on the layout of the rooms and study requirements Clinvet will be able to house an additional 800 to 1,000 felines and an additional 100 to 230 canines; a significant increase in our current capacity.

Additionally, this expansion will provide Clinvet the opportunity to establish and increase the size of their re-use colonies to increase efficiency and enable faster start-up times for studies. In conjunction with enlarging the physical capacity, Clinvet will also be adding approximately 9 additional staff members, transitioning from Marshall, with a total staff compliment of 30 highly-qualified and experienced employees working for Clinvet at the Waverly facility. Although some buildings and staff will transition to Clinvet, Marshall will continue to maintain facilities and staff at this site dedicated to production activities. New procedures will ensure that production and research activities are kept segregated.

We are excited with the continued success and expansion of our partnership, and we want to thank you again for your continued support of our respective businesses. We would also like to wish you all the best with your business during this uncertain period and want to assure you of our unwavering support during this time.

Kind regards

Theo Erasmus CEO, Clinvet

Scott Marshall

CEO, Marshall BioResources

## **About Marshall Bioresources:**

Marshall BioResources is a global provider of purpose bred animals and related services for biomedical research. For over 80 years our animals have contributed to the development of life saving therapies and treatments for humans and animals alike. We hold ourselves to the highest standards of health and quality, and <u>AAALAC</u> accreditation serves to enhance our top commitment to animal care and welfare.(www.marshallbio.com)

## **About Clinvet:**

Clinvet and its partner companies have been providing research solutions and services to the animal health industry since 1999. A group of partner companies enables Clinvet to provide a wide range of related services in support of laboratory and clinical trials performed on veterinary health products for the animal health sector. With a wealth of experience, Clinvet has for many years been able to support leading animal health companies in ground-breaking research and clinical development programs. (www.clinvet.com)